Biograph 40 truepoint with truev

Patients fasted for 6 hours before the examination to ensure blood glucose levels below 150 mg/dL. Furosemide 20 mg was given to increase renal excretion of the tracer and avoid accumulation in non-malignant cells. Examinations were performed 1 hour after an intravascular injection of 5.18 MBq/kg of [18F]-FDG using a hybrid FDG-PET/CT device (Biograph 40 TruePoint with TrueV, Siemens Medical Solutions, Erlangen, Germany) consisting of a high-resolution 3D PET and a 40-row CT. Patients were in a supine position with arms along the body and a field of view from the head to the feet. A whole-body, free-breathing, spiral, low-dose CT acquisition (60 mAs; 120 kV; collimation 2 mm × 5 mm; pitch 1.5) was performed for PET-attenuation correction, followed by the emission scan using a 3D-row action maximum likelihood algorithm (RAMLA) for reconstruction (6–7 bed positions; field of view (FOV) 50 cm; 128 × 128 matrix). A diagnostic contrast-enhanced CT was conducted (100 mAs, 120 kV, collimation 2 × 5 mm, pitch 1) after i.v. administration of 80–90 mL of non-ionic iodinated contrast agent (Iopamiro 300, Bracco, Shanghai, China) in the venous phase (60–70 seconds delay). Finally, PET images were fused with contrast-enhanced CT. The total duration of each examination was about 45 minutes.